WHAT IS CLAIMED:

1. Use of an effective amount of an anti-cMET antibody drug conjugate (ADC) in the manufacture of a medicament for treating a cMET-positive solid tumor cancer in a human subject having said cancer, wherein:

(a) the antibody component of the ADC exhibits cMET-specific pH-dependent binding; and

(b), the antibody comprises heavy and light chain CDRs present in the amino acid sequences as set forth in one of the following pairs: SEQ ID NOs: 15 & 16; SEQ ID NOs: 5 & 6; SEQ ID NOs: 7 & 8; SEQ ID NOs: 9 & 10; SEQ ID NOs: 11 & 12; SEQ ID NOs: 13 & 14; SEQ ID NOs: 17 & 18; SEQ ID NOs: 19 & 20; SEQ ID NOs: 21 & 22; SEQ ID NOs: 23 & 24; SEQ ID NOs: 25 & 26; SEQ ID NOs: 27 & 28; SEQ ID NOs: 29 & 30; SEQ ID NOs: 31 & 32; and SEQ ID NOs: 33 & 34.

2. Use of an effective amount of an anti-cMET antibody drug conjugate (ADC) in the manufacture of a medicament for treating a cMET-positive solid tumor cancer having low or intermediate expression of cMET in a human subject previously identified or selected as having said cancer, wherein the antibody component of the ADC exhibits cMET-specific pH-dependent binding.

3. A pharmaceutical composition comprising a therapeutically effective amount of a pH-dependent anti-cMET antibody drug conjugate (ADC), comprising the heavy and light chain CDRs and/or entire heavy chain variable domain (HCVD) and light chain variable domain (LCVD) present in the amino acid sequences as set forth in one of the following pairs of SEQ ID NOs: SEQ ID NOs: 15 & 16; SEQ ID NOs: 5 & 6; SEQ ID NOs: 7 & 8; SEQ ID NOs: 9 & 10; SEQ ID NOs: 11 & 12; SEQ ID NOs: 13 & 14; SEQ ID NOs: 17 & 18; SEQ ID NOs: 19 & 20; SEQ ID NOs: 21 & 22; SEQ ID NOs: 23 & 24; SEQ ID NOs: 25 & 26; SEQ ID NOs: 27 & 28; SEQ ID NOs: 29 & 30; SEQ ID NOs: 31 & 32; and SEQ ID NOs: 33 & 34; and/or wherein the ADC comprises two heavy chains each having the sequence set forth in SEQ ID NO: 75 and two light chains each having the sequence set forth in SEQ ID NO: 82, wherein each light chain constant domain comprises the sequence set forth in SEQ ID NO: 158 and a linker-drug conjugated thereto at the cysteine located at amino acid position 98 of SEQ ID NO: 158.

4. The use according to any one of claims 1 or 2, wherein the solid tumor cancer has a cMET immunohistochemistry score of 1+, 2+, or 3+, and/or an H-score of at least about 50 to 300.

5. The use according to any one of claims 1, 2, or 4, wherein the solid tumor cancer is non-small cell lung cancer (NSCLC).

6. The use according to claim 5, wherein the NSCLC is selected from non-squamous NSCLC, squamous NSCLC, and not otherwise specified NSCLC.

7. The use according to any one of claims 1, 2, 4, 5, or 6, wherein at least about 10% of tumor cells have a cMET expression level of at least 1+ as scored by immunohistochemistry.

8. The use according to claim 7, wherein:

(a) at least about 25% of tumor cells have an IHC score of 1+ or 2+; or

(b) at least about 10% of tumor cells have an IHC score of 1+ and no more than about 5% of tumor cells have an IHC score of 2+ or 3+.

9. The use according to any one of claims 1, 2, or 4 to 8, wherein the cancer has developed resistance to a targeted therapy against an actionable mutation in a gene selected from EGFR, ALK, KRAS, ROS, BRAF, NTRK1/2/3, MET, RET, and ERBB2.

10. The use according to claim 9, wherein the actionable mutation is selected from:

(a) an EGFR gene mutation selected from an exon 20 T790M substitution, an exon 20 C797X substitution, an exon 21 L858R substitution, and an exon 19 deletion;

(b) an ALK gene rearrangement;

(c) a KRAS gene mutation;

(d) a MET exon 14 skipping mutation; or

(e) an ERBB2 gene amplification, mutation, or overexpression.

11. The use according to any one of claims 1, 2, or 4 to 10, wherein the anti-cMET ADC is to be administered as monotherapy or adjunctive to an additional anticancer agent.

12. The use according to claim 11, wherein the additional anticancer agent is an inhibitor of EGFR, ALK, KRAS, BRAF, MET, ROS1, NTRK1/2/3, RET, ERBB2, PD-1, or PD-L1.

13. The use according to any one of claims 1, 2, or 4 to 12, wherein the anti-cMET antibody comprises:

(a) a VH chain comprising the amino acid sequences as set forth in SEQ ID NO: 236, SEQ ID NO: 237, and SEQ ID NO: 238; and

(b) a VL chain comprising the amino acid sequences as set forth in SEQ ID NO: 239, SEQ ID NO: 240, and SEQ ID NO: 241.

14. The use according to claim 13, wherein the anti-cMET antibody comprises:

(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 75; and

(b) a light chain comprising the amino acid sequence of SEQ ID NO: 82.

15. The use according to any one of claims 1, 2, or 4 to 14, wherein the ADC comprises a linker cleavable by a lysosomal enzyme and wherein the drug component is an auristatin.

16. The use according to claim 15, wherein the linker comprises a peptide selected from Val-Cit, Cit-Val, and Ala-Val.

17. The pharmaceutical composition according to claim 3, wherein the linker-drug comprises vcMMAE.

18. The pharmaceutical composition according to claim 3 or 17, wherein the composition further comprises L-Histidine, L-Histidine HCl monohydrate, D (+)-Trehalose dihydrate, and Polysorbate 80.